Pharmacokinetic and economic evaluation of piperacillin/tazobactam administered as either continuous or intermittent infusion with once-daily gentamicin

Infectious Diseases in Clinical Practice

Volumn 8, Issue 4, 1999, Pages 195-200

  Richerson, Mark A ^a,b   Ambrose, Paul G ^a,c   Bui, Khanh Q ^a   Grant, Edward ^a   Nicolau, David P ^a   Nightingale, Charles H ^a   Quintiliani, Richard ^a  

^a HARTFORD HOSPITAL   (United States)

^b Fort Sam Houston   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; GENTAMICIN; PIPERACILLIN PLUS TAZOBACTAM;

ADULT; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; CONTINUOUS INFUSION; DRUG BLOOD LEVEL; DRUG COST; DRUG HALF LIFE; DRUG INTERMITTENT THERAPY; FEMALE; HUMAN; HUMAN EXPERIMENT; INTERMETHOD COMPARISON; MALE; NORMAL HUMAN;

EID: 0032930279     PISSN: 10569103     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019048-199905000-00008     Document Type: Article

References (15)

1. Nicolau DP, Freeman CD, Belliveau PP, et al. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother 1995;39:650-5.
2. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing in mice and men. Clin Infect Dis 1998;26:1-12.
3. Gerber AU, Craig WA, Brugger HP, et al. Impact of closing intervals on activity of gentamicin and ticarcillin against Pseudomonas aeruginosa in granulocytopenic mice. J Infect Dis 1983;147:910-7.
4. Benko AS, Cappelletty DM, Kruse JA, et al. Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections. Antimicrob Agents Chemother 1996;40:691-5.
5. Bryan CS, Talwani R, Stinson, MS. Penicillin dosing for pneumococcal pneumonia. Chest 1997;112:1657-64.
6. Mouton JW, Vinks A. Is continuous infusion of β-lactam antibiotics worthwhile? Efficacy and pharmacokinetic considerations. J Antimicrob Chemother 1996;38: 5-15.
7. Vinks AA, Brimicombe RW, Heijerman HG, et al. Continuous infusion of ceftazidime in cystic fibros s patients during home treatment: clinical outcome, microbiology and pharmacokinetics. J Antimicrob Chemother 1997; 40:125-33.
8. Marietta IB, Russo ME, Saxon BJ, et al. Gentamicin inactivation by piperacillin or carbenacillin in patients with end-stage renal disease. Antimicrob Agents Chemother 1982;21:268-73.
9. Russo ME. Penicillin-aminoglycoside inactivation: another possible mechanism of interaction. Am J Hosp Pharm 1980;37:702-4.
10. Pickering LK, Rutherford I. Effect of concentration and time upon inactivation of tobramycin, gentamicin, netilmicin and amikacin by azlocillin, carbenicillin, mecillinam and piperacillin. J Pharmacol Exp Ther 1981;217: 345-9.
11. Stevens P, Young LS. Simple method of elimination of aminoglycosides from serum to permit assay of other antimicrobial agents. Antimicrob Agents Chemother 1977; 12:286-7.
12. Klepser ME, Patel KB, Nicolau DP, et al. Comparison of the bactericidal activities of ofloxacin and ciprofloxacin alone and in combination with ceftazidime and piperacillin against clinical strains of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1995;39:2503-10.
13. Hitt CM, Nightingale CH, Quintiliani R, et al. Cost comparison of single daily doses of ceftriaxone versus continuous infusion of cefotaxime. Am J Health Syst Pharm 1997;54:1614-8.
14. Hitt CM, Klepser ME, Nightingale CH, et al. Pharmacoeconomic impact of once daily aminoglycoside administration. Pharmacotherapy 1997;17:810-4.
15. Hitt CM, Patel KB, Nicolau DP, et al. Influence of piperacillin-tazobactam on pharmacokinetics of gentamicin given once daily. Am J Health Syst Pharm 1997;54: 2704-8.